MIRA Pharmaceuticals (NASDAQ: MIRA) has announced its Board's approval for the acquisition of SKNY Pharmaceuticals, with a combined enterprise value exceeding $60 million based on independent valuations. The merger, pending shareholder approval, includes a $5 million contribution from SKNY in cash or assets at closing. Moore Financial Consulting valued SKNY at $30.5 million and MIRA at $30 million. SKNY's lead compound, SKNY-1, targets both obesity and nicotine dependence through a novel mechanism modulating CB1/CB2 cannabinoid receptors and MAO-B. The acquisition positions MIRA in two high-growth markets: the global weight loss drug market (projected to exceed $150 billion by 2030) and the U.S. smoking cessation market (expected to reach $50.90 billion by 2030).
MIRA Pharmaceuticals (NASDAQ: MIRA) ha annunciato l'approvazione da parte del suo Consiglio di Amministrazione per l'acquisizione di SKNY Pharmaceuticals, con un valore aziendale combinato superiore a 60 milioni di dollari secondo valutazioni indipendenti. La fusione, in attesa dell'approvazione degli azionisti, prevede un contributo di 5 milioni di dollari da parte di SKNY in contanti o beni al momento della chiusura. Moore Financial Consulting ha valutato SKNY a 30,5 milioni di dollari e MIRA a 30 milioni di dollari. Il composto principale di SKNY, SKNY-1, agisce sia sull'obesità che sulla dipendenza da nicotina tramite un meccanismo innovativo che modula i recettori cannabinoidi CB1/CB2 e MAO-B. L'acquisizione posiziona MIRA in due mercati ad alta crescita: il mercato globale dei farmaci per la perdita di peso (con una previsione di superare i 150 miliardi di dollari entro il 2030) e il mercato statunitense per la cessazione del fumo (che si prevede raggiungerà i 50,90 miliardi di dollari entro il 2030).
MIRA Pharmaceuticals (NASDAQ: MIRA) ha anunciado la aprobación de su Junta Directiva para la adquisición de SKNY Pharmaceuticals, con un valor empresarial combinado que supera los 60 millones de dólares según valoraciones independientes. La fusión, pendiente de la aprobación de los accionistas, incluye una contribución de 5 millones de dólares por parte de SKNY en efectivo o activos al cierre. Moore Financial Consulting valoró SKNY en 30,5 millones de dólares y MIRA en 30 millones de dólares. El compuesto principal de SKNY, SKNY-1, está dirigido tanto a la obesidad como a la dependencia de la nicotina mediante un mecanismo novedoso que modula los receptores cannabinoides CB1/CB2 y MAO-B. La adquisición posiciona a MIRA en dos mercados de alto crecimiento: el mercado global de medicamentos para la pérdida de peso (con proyecciones que superan los 150 mil millones de dólares para 2030) y el mercado estadounidense para dejar de fumar (que se espera alcance los 50,90 mil millones de dólares para 2030).
MIRA Pharmaceuticals(NASDAQ: MIRA)는 독립적인 평가를 바탕으로 기업가치 합계가 6천만 달러를 초과하는 SKNY Pharmaceuticals 인수를 이사회에서 승인했다고 발표했습니다. 주주 승인 대기 중인 이번 합병에는 SKNY가 종료 시점에 현금 또는 자산으로 5백만 달러를 출자하는 조건이 포함되어 있습니다. Moore Financial Consulting은 SKNY를 3,050만 달러, MIRA를 3,000만 달러로 평가했습니다. SKNY의 주요 화합물인 SKNY-1은 CB1/CB2 칸나비노이드 수용체와 MAO-B를 조절하는 새로운 메커니즘을 통해 비만과 니코틴 의존성을 동시에 표적으로 합니다. 이번 인수로 MIRA는 두 개의 고성장 시장, 즉 2030년까지 1,500억 달러를 초과할 것으로 예상되는 글로벌 체중 감량 약물 시장과 2030년까지 509억 달러에 이를 것으로 예상되는 미국 금연 시장에 진입하게 됩니다.
MIRA Pharmaceuticals (NASDAQ : MIRA) a annoncé l'approbation de son conseil d'administration pour l'acquisition de SKNY Pharmaceuticals, avec une valeur d'entreprise combinée dépassant 60 millions de dollars selon des évaluations indépendantes. La fusion, en attente de l'approbation des actionnaires, inclut une contribution de 5 millions de dollars de SKNY en espèces ou en actifs à la clôture. Moore Financial Consulting a évalué SKNY à 30,5 millions de dollars et MIRA à 30 millions de dollars. Le composé principal de SKNY, SKNY-1, cible à la fois l'obésité et la dépendance à la nicotine via un mécanisme novateur modulant les récepteurs cannabinoïdes CB1/CB2 et MAO-B. Cette acquisition positionne MIRA sur deux marchés à forte croissance : le marché mondial des médicaments pour la perte de poids (prévu pour dépasser 150 milliards de dollars d'ici 2030) et le marché américain du sevrage tabagique (attendu pour atteindre 50,90 milliards de dollars d'ici 2030).
MIRA Pharmaceuticals (NASDAQ: MIRA) hat die Zustimmung seines Vorstands zur Übernahme von SKNY Pharmaceuticals bekannt gegeben, wobei der kombinierte Unternehmenswert laut unabhängigen Bewertungen 60 Millionen US-Dollar übersteigt. Die Fusion, die noch der Zustimmung der Aktionäre bedarf, beinhaltet einen Beitrag von SKNY in Höhe von 5 Millionen US-Dollar in bar oder Vermögenswerten zum Abschluss. Moore Financial Consulting bewertete SKNY mit 30,5 Millionen US-Dollar und MIRA mit 30 Millionen US-Dollar. Der Hauptwirkstoff von SKNY, SKNY-1, zielt sowohl auf Fettleibigkeit als auch auf Nikotinabhängigkeit ab und wirkt über einen neuartigen Mechanismus, der die CB1/CB2-Cannabinoidrezeptoren und MAO-B moduliert. Die Übernahme positioniert MIRA in zwei wachstumsstarken Märkten: dem globalen Markt für Gewichtsreduktionsmedikamente (mit einer Prognose von über 150 Milliarden US-Dollar bis 2030) und dem US-amerikanischen Markt für Raucherentwöhnung (der voraussichtlich 50,90 Milliarden US-Dollar bis 2030 erreichen wird).
Positive
Combined enterprise value of over $60 million strengthens market position
Access to two high-growth markets: weight loss ($150B by 2030) and smoking cessation ($50.9B by 2030)
SKNY-1's unique multi-target mechanism offers differentiated approach to obesity and nicotine dependence
$5 million in cash/assets contribution from SKNY at closing
Negative
Merger still requires shareholder approval from both companies
Early-stage development status of SKNY-1 implies significant development risks
Will face competition from established GLP-1 treatments in weight loss market
Insights
MIRA's acquisition of SKNY expands pipeline into obesity and addiction markets, adding $30.5M in enterprise value plus $5M cash.
MIRA Pharmaceuticals has secured board approval for its acquisition of SKNY Pharmaceuticals in a transaction that combines two similarly-sized enterprises with a total valuation exceeding $60 million. The independent valuation conducted by Moore Financial Consulting assigns $30.5 million to SKNY and $30 million to MIRA, providing third-party validation for the deal structure.
The strategic rationale centers on SKNY's lead compound SKNY-1, which targets the intersection of metabolic disorders and addiction through a multi-receptor mechanism. This novel approach potentially addresses two substantial markets: the global weight loss sector projected to reach $150 billion by 2030 and the U.S. smoking cessation market expected to grow from $28.11 billion to $50.9 billion during the same period.
Notably, SKNY will contribute $5 million in cash or assets at closing, strengthening the combined company's balance sheet. While the scientific approach targeting CB1/CB2 cannabinoid receptors and MAO-B modulation presents a differentiated mechanism from current GLP-1 therapies dominating the obesity market, investors should recognize that SKNY-1 appears to be in early development stages with limited disclosed clinical data.
The transaction still requires shareholder approval from both companies, representing a remaining hurdle before completion. This acquisition represents a pivotal expansion for MIRA beyond its current CNS-focused pipeline into metabolic and addiction therapeutics, diversifying its portfolio while maintaining a consistent focus on neurological mechanisms and receptor pharmacology.
With valuations confirmed by the board, MIRA advances strategic acquisition targeting obesity and nicotine dependence, which includes a $5 million contribution in cash or assets from SKNY to be transferred at closing.
MIAMI, FLORIDA / ACCESS Newswire / May 8, 2025 / MIRA Pharmaceuticals, Inc. (Nasdaq:MIRA) ("MIRA" or the "Company"), a clinical-stage pharmaceutical company developing novel therapeutics for neurologic, neuropsychiatric, and metabolic disorders, today announced that its Board of Directors has approved the planned acquisition of SKNY Pharmaceuticals, Inc. (the "Merger"), following the completion of independent valuation reports on both companies. The Merger remains subject to MIRA and SKNY's shareholder approval.
A third-party analysis conducted by Moore Financial Consulting ("Moore") assigned SKNY Pharmaceuticals an enterprise value of approximately $30.5 million, based on a risk-adjusted net present value (rNPV) of its lead compound, SKNY-1. MIRA was separately valued by Moore at $30 million, further validating the strength and synergy of the combined pipeline. As outlined in the previously announced binding letter of intent for the merger between MIRA and SKNY-1, upon the closing, SKNY must hold at least $5 million in cash or other assets, to be transferred at closing, and the Company is preparing a filing with the U.S. Securities and Exchange Commission to seek shareholder approval.
As MIRA advances this merger, the combined enterprise value (based on Moore's valuations) of over $60 million represents a strong platform for expansion into high-value therapeutic markets. According to MIRA CEO Erez Aminov, the acquisition "brings together two pipelines, two market opportunities, and one unified strategy, developing targeted, first-in-class therapies for urgent public health needs."
Targeting Major Markets with a Differentiated Mechanism
SKNY-1 is being developed as a next-generation oral therapeutic designed to modulate CB1 and CB2 cannabinoid receptors, as well as monoamine oxidase B (MAO-B)-an enzyme involved in dopamine metabolism and addiction regulation. This multi-target mechanism is being evaluated for its potential to address both metabolic dysfunction and nicotine dependence, providing a differentiated therapeutic alternative in two of the most urgent health markets globally.
The global weight loss drug market is projected to surpass $150 billion by 2030, driven by growing demand for safer and more tolerable alternatives to GLP-1-based injectables (Source: Reuters).
The U.S. smoking cessation market is projected to grow from $28.11 billion in 2024 to $50.90 billion by 2030, at a CAGR of 10.4% (Source: Grand View Research).
These are large, underserved markets with limited innovation, and MIRA's leadership believes the addition of SKNY-1 to the Company's pipeline enhances its ability to compete in both.
Dr. Itzchak Angel, Chief Scientific Advisor at MIRA, noted that SKNY-1's pharmacological profile, particularly its combined activity on both MAO-B and cannabinoid receptors, makes it a unique and promising candidate for craving, addiction and metabolic conditions with a sound neurochemical basis. "From a scientific perspective, this is a rationally designed molecule that addresses the biological complexity of both obesity and addiction," said Dr. Angel. "The early data are promising, and I'm looking forward to advancing its development."
Strategic Value for the Future
With both companies independently valued by Moore at approximately $30 million, MIRA believes this transaction creates a platform with scale, differentiated science, and a pipeline built to target urgent unmet needs. The Company views this merger as a foundation for long-term growth and innovation.
This press release and the statements of MIRA's management related thereto contain "forward-looking statements," which are statements other than historical facts made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements may be identified by words such as "aims," "anticipates," "believes," "could," "estimates," "expects," "forecasts," "goal," "intends," "may," "plans," "possible," "potential," "seeks," "will," and variations of these words or similar expressions that are intended to identify forward-looking statements. Any statements in this press release that are not historical facts may be deemed forward-looking. Any forward-looking statements in this press release are based on MIRA's current expectations, estimates, and projections only as of the date of this release and are subject to a number of risks and uncertainties (many of which are beyond MIRA's control) that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements, including related to MIRA's potential merger with SKNY Pharmaceuticals, Inc. These and other risks concerning MIRA's programs and operations are described in additional detail in the Annual Report on Form 10-K for the year ended December 31, 2024, and other SEC filings, which are on file with the SEC at www.sec.gov and MIRA's website at https://www.mirapharmaceuticals.com/investors/sec-filings. MIRA explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law.
What is the enterprise value of the MIRA and SKNY merger?
The combined enterprise value of the merger exceeds $60 million, with SKNY valued at $30.5 million and MIRA at $30 million, based on independent valuations by Moore Financial Consulting.
What markets will MIRA target with SKNY-1 after the acquisition?
SKNY-1 targets two major markets: the global weight loss drug market (projected to reach $150 billion by 2030) and the U.S. smoking cessation market (expected to reach $50.90 billion by 2030).
How does SKNY-1's mechanism of action work?
SKNY-1 works through a multi-target mechanism that modulates CB1 and CB2 cannabinoid receptors and MAO-B (monoamine oxidase B), targeting both metabolic dysfunction and nicotine dependence.
What conditions must be met for the MIRA-SKNY merger to complete?
The merger requires shareholder approval from both MIRA and SKNY shareholders, and SKNY must contribute $5 million in cash or assets at closing.
What is the strategic rationale behind MIRA's acquisition of SKNY?
The acquisition combines two pipelines targeting urgent public health needs, providing MIRA with access to high-value therapeutic markets in obesity and smoking cessation with a differentiated therapeutic approach.
An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
